Home Other Building Blocks Bay 60-7550

Bay 60-7550

CAS No.:
439083-90-6
Catalog Number:
AG00D7YO
Molecular Formula:
C27H32N4O4
Molecular Weight:
476.5674
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$423
- +
10mg
98%
1 week
United States
$690
- +
100mg
98%
1 week
United States
$3723
- +
Product Description
Catalog Number:
AG00D7YO
Chemical Name:
Bay 60-7550
CAS Number:
439083-90-6
Molecular Formula:
C27H32N4O4
Molecular Weight:
476.5674
MDL Number:
MFCD08702694
IUPAC Name:
2-[(3,4-dimethoxyphenyl)methyl]-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
InChI:
InChI=1S/C27H32N4O4/c1-17-25-27(33)29-24(16-20-13-14-22(34-3)23(15-20)35-4)30-31(25)26(28-17)21(18(2)32)12-8-11-19-9-6-5-7-10-19/h5-7,9-10,13-15,18,21,32H,8,11-12,16H2,1-4H3,(H,29,30,33)/t18-,21+/m1/s1
InChI Key:
MYTWFJKBZGMYCS-NQIIRXRSSA-N
SMILES:
COc1cc(ccc1OC)Cc1nn2c(nc(c2c(=O)[nH]1)C)[C@H]([C@H](O)C)CCCc1ccccc1
UNII:
ZRN7LZK9TQ
Properties
Complexity:
728  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0
Exact Mass:
476.242g/mol
Formal Charge:
0
Heavy Atom Count:
35  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
476.577g/mol
Monoisotopic Mass:
476.242g/mol
Rotatable Bond Count:
10  
Topological Polar Surface Area:
98A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.2  
Literature
Title Journal
Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice. Psychopharmacology 20160201
Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation 20140805
Phosphodiesterase 2A localized in the spinal cord contributes to inflammatory pain processing. Anesthesiology 20140801
X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity. Journal of the American Chemical Society 20130814
Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway. The international journal of neuropsychopharmacology 20130501
Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neuro-Signals 20130101
Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behavioural brain research 20130101
Pendrin protein abundance in the kidney is regulated by nitric oxide and cAMP. American journal of physiology. Renal physiology 20120915
Mechanisms of carbon monoxide attenuation of tubuloglomerular feedback. Hypertension (Dallas, Tex. : 1979) 20120601
PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic research in cardiology 20100501
Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. The Journal of pharmacology and experimental therapeutics 20091101
A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors. Molecular pharmaceutics 20090101
Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. European journal of pharmacology 20081214
ANP-mediated cGMP signaling and phosphodiesterase inhibition in the rat cervical spinal cord. Journal of chemical neuroanatomy 20060601
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 20041201
Properties